Over the last 12 months, one Protagenic Therapeutics, Inc. ew officers and board members bought shares at market prices, about $31,000 in total, and none of them sold.
ARMEN GARO H (Chair) made the biggest buy, worth around $13,000.
2 investment managers listed PTIX in their latest 13F filings (Q2 2026); more funds sold than bought. Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | ARMEN GARO H | Chair | Buy | 20,000 | $0.65 | $13K | SEC |
| Aug 20, 2026 | ARMEN GARO H | Chair | Buy | 16,634 | $0.59 | $10K | SEC |
| Aug 20, 2026 | ARMEN GARO H | Chair | Buy | 2,700 | $0.35 | $945 | SEC |
| Aug 12, 2026 | ARMEN GARO H | Chair | Buy | 2,220 | $0.32 | $710 | SEC |
| Aug 10, 2026 | ARMEN GARO H | Chair | Buy | 685 | $0.22 | $151 | SEC |
| Aug 6, 2026 | ARMEN GARO H | Chair | Buy | 5,000 | $0.26 | $1K | SEC |
| Aug 3, 2026 | ARMEN GARO H | Chair | Buy | 26,291 | $0.18 | $5K | SEC |
| Oct 13, 2023 | Arrow Alexander K. | CFO | Buy | 8,000 | $0.81 | $6K | SEC |
In the last 12 months Protagenic Therapeutics, Inc. ew insiders made open-market purchases worth about $31,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in PTIX was filed on 2026-08-24.
2 investment managers reported holding PTIX in SEC Form 13F filings for Q2 2026.
No congressional trades in PTIX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).